Functional genomic characterization of cancer genomes

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 81, Issue 1, 2016, Pages 237-246

  Howard, Thomas P ^a,b   Vazquez, Francisca ^a,b   Tsherniak, Aviad ^b   Hong, Andrew L ^a,b,c   Rinne, Mik ^a,b   Aguirre, Andrew J ^a,b   Boehm, Jesse S ^b   Hahn, William C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COPY NUMBER VARIATION; CRISPR CAS SYSTEM; ESSENTIAL GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GENE; ANIMAL; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN GENOME; MUTATION; NEOPLASM;

ALLELES; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION; NEOPLASMS;

EID: 85020969821     PISSN: 00917451     EISSN: 19434456     Source Type: Book Series    
DOI: 10.1101/sqb.2016.81.031070     Document Type: Article

References (80)

1. Aguirre AJ, Meyers RM,Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, et al. 2016. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discov 6: 914-929
2. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S,Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607
4. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, NijkampW, Weigelt B, et al. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437
5. Boehm JS, Hahn WC. 2011. Towards systematic functional characterization of cancer genomes. Nat Rev Genet 12: 487-498
6. Booker M, Samsonova AA, Kwon Y, Flockhart I, Mohr SE, Perrimon N. 2011. False negative rates in Drosophila cellbased RNAi screens: A case study. BMC Genomics 12: 50
7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, et al. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276-283
8. Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. 2016. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proc Natl Acad Sci 113: E3892-E3900
9. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, et al. 2009. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16: 324-335
10. Buehler E, Chen YC, Martin S. 2012. C911: A bench-level control for sequence specific siRNA off-target effects. PLoS One 7: e51942
11. Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, et al. 2015. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527: 192-197
12. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. 2012. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404
13. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, Scott DA, Song J, Pan JQ,Weissleder R, et al. 2015. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160: 1246-1260
14. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, et al. 2011a. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci 108: 12372-12377
15. CheungHW, Du J, Boehm JS, He F,Weir BA,Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, et al. 2011b. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1: 608-625
16. Cho SW, Kim S, Kim JM, Kim JS. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230-232
17. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, JiangW, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823
18. Cowley GS,Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, et al. 2014. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 1: 140035
19. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. 2014. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 13: 828-851
20. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. 2013. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126
21. Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, et al. 2014. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci 111: 1102-1107
22. Echeverri CJ, Perrimon N. 2006. High-throughput RNAi screening in cultured cells: A user's guide. Nat Rev Genet 7: 373-384
23. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, et al. 2006. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3: 777-779
24. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: l1
25. Garraway LA, Lander ES. 2013. Lessons from the cancer genome. Cell 153: 17-37
26. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, et al. 2011. Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer 47: 2493-2511
27. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, et al. 2004. The status, quality, and expansion of the NIH fulllength cDNA project: The Mammalian Gene Collection (MGC). Genome Res 14: 2121-2127
28. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al. 2011. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci 108: 18708-18713
29. Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, et al. 2013. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 3: 1044-1057
30. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674
31. Helming KC, Wang X, Roberts CW. 2014a. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309-317
32. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, et al. 2014b. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20: 251-254
33. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, et al. 2014. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci 111: 3128-3133
34. Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, et al. 2016. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun 7: 11987
35. Hsu PD, Lander ES, Zhang F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157: 1262-1278
36. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. 2005. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000
37. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637
38. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. 2006. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187
39. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821
40. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. 2013. RNAprogrammed genome editing in human cells. Elife 2: e00471
41. Kaelin WG Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698
42. KaelinWGJr. 2012. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 337: 421-422
43. Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, Yang X, Lubonja R, Tran N, Nguyen C, et al. 2016. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. Cancer Discov 6: 714-726
44. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, et al. 2015. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517: 583-588
45. Korkmaz G, Lopes R, Ugalde AP, Nevedomskaya E, Han R, Myacheva K, Zwart W, Elkon R, Agami R. 2016. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol 34: 192-198
46. Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F,Weir BA, Fitzgerald ME, Tanaka M, et al. 2016. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351: 1214-1218
47. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, et al. 2002. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31: 133-134
48. LiW, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS. 2014. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol 15: 554
49. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, et al. 2008. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci 105: 20380-20385
50. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR,Westbrook TF, Wong KK, Elledge SJ. 2009. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848
51. Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC. 2015. The tyrosine kinase adaptor protein FRS2 is oncogenic and amplified in high-grade serous ovarian cancer. Mol Cancer Res 13: 502-509
52. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823-826
53. Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A, et al. 2003. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3: 297-302
54. Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, Tsherniak A, Besche HC, Rosenbluh J, Shehata S, et al. 2012. Cancer vulnerabilities unveiled by genomic loss. Cell 150: 842-854
55. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, et al. 2013. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 73: 5508-5518
56. ORFeome Collaboration. 2016. The ORFeome Collaboration: A genome-scale human ORF-clone resource. Nat Methods 13: 191-192
57. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. 2009. siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev 61: 746-759
58. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, et al. 2016. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 12: 109-116
59. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, et al. 2012. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4: 147ra112
60. Rual JF, Hirozane-Kishikawa T, Hao T, Bertin N, Li S, Dricot A, Li N, Rosenberg J, Lamesch P, Vidalain PO, et al. 2004. Human ORFeome version 1.1: A platform for reverse proteomics. Genome Res 14: 2128-2135
61. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al. 2009. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834
62. Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, Jones V, Bodycombe NE, Soule CK, Gould J, et al. 2015. Harnessing connectivity in a large-scale smallmolecule sensitivity dataset. Cancer Discov 5: 1210-1223
63. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert B L, Root De, Doench JG, et al. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84-87
64. Shao DD, Tsherniak A, Gopal S, Weir BA, Tamayo P, Stransky N, Schumacher SE, Zack TI, Beroukhim R, Garraway LA, et al. 2013. ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 23: 665-678
65. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al. 2014. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4: 80-93
66. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. 2015. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 33: 661-667
67. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724
68. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M,Yanagitani N, Kaira K, et al. 2011. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 10: 336-346
69. Verdine GL, Walensky LD. 2007. The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264-7270
70. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558
71. Wallace J, Hu R, Mosbruger TL, Dahlem TJ, Stephens WZ, Rao DS, Round JL, O'Connell RM. 2016. Genome-wide CRISPR-Cas9 screen identifies microRNAs that regulate myeloid leukemia cell growth. PLoS One 11: e0153689
72. Wang T,Wei JJ, Sabatini DM, Lander ES. 2014. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343: 80-84
73. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, Sabatini DM. 2015. Identification and characterization of essential genes in the human genome. Science 350: 1096-1101
74. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, et al. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell 121: 837-848
75. Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492
76. Wilson BG, Helming KC,Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, Roberts CW. 2014. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 34: 1136-1144
77. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y, Lubonja R, Thomas SR, Alkan O, Bhimdi T, et al. 2011. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8: 659-661
78. Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, Taylor BR, Crenshaw A, Gould JZ, Tamayo P, et al. 2016. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34: 419-423
79. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al. 2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267
80. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, et al. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864